Physician profile
Sarah E West
NPI 1629149083
$3,007.49
in general payments reported to CMS, 2019-2025
37 companies · $877 in 2025
The $877 reported for 2025 was more than what 94% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.57 · 2022: $366 · 2023: $911 · 2024: $819 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $380.43 | 2022-2025 | Injectafer, Enhertu |
| Janssen Biotech, INC. | $316.61 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $249.52 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Novartis Pharmaceuticals Corporation | $224.82 | 2023-2025 | |
| Abbvie INC. | $170.31 | 2022-2025 | Venclexta |
| Eisai INC. | $152.62 | 2022-2025 | |
| Astellas Pharma US INC | $120.50 | 2022-2025 | Padcev, Vyloy |
| Servier Pharmaceuticals LLC | $117.79 | 2023-2025 | |
| Genzyme Corporation | $109.71 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $105.15 | 2024-2025 | Imfinzi, Calquence |
| Emd Serono, INC. | $98.84 | 2022-2023 | Bavencio |
| Seagen INC. | $85.39 | 2022-2023 | Tukysa |
| Sobi, INC | $74.50 | 2022-2025 | |
| Beigene USA, INC. | $73.24 | 2021-2024 | Brukinsa |
| Genentech USA, INC. | $60.30 | 2024-2025 | Itovebi, Phesgo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $53.99 | 2023-2024 | Cabometyx |
| Merck Sharp & Dohme LLC | $52.16 | 2022-2024 | Keytruda |
| Pfizer INC. | $46.24 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.67 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $44.50 | 2023-2024 | Givlaari |
| Tersera Therapeutics LLC | $44.26 | 2023 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $38.22 | 2022-2024 | Onivyde |
| Puma Biotechnology, INC. | $33.99 | 2023-2024 | |
| Blueprint Medicines Corporation | $32.08 | 2023-2025 | Ayvakit |
| Amgen INC. | $29.85 | 2022-2023 | Blincyto, Kyprolis |
| Taiho Oncology, INC. | $27.90 | 2024 | |
| Pharmacosmos Therapeutics INC. | $25.75 | 2025 | Monoferric |
| Karyopharm Therapeutics INC. | $24.87 | 2025 | Xpovio |
| Stryker Corporation | $23.42 | 2025 | Clottriever Bold Catheter |
| Caris Mpi, INC. | $21.89 | 2025 | Mi Cancer Seek |
| Novocure INC. | $21.85 | 2024 | Optune |
| Regeneron Healthcare Solutions, INC. | $21.25 | 2023 | Libtayo |
| Foundation Medicine, INC. | $19.70 | 2021 | |
| Legend Biotech USA INC. | $18.74 | 2024 | |
| Blue Earth Diagnostics | $15.04 | 2022 | |
| Aveo Pharmaceuticals, INC. | $14.18 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.21 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.